ProQR Therapeutics (PRQR) Notes Payables (2013 - 2023)

ProQR Therapeutics (PRQR) has reported Notes Payables for 11 consecutive years, with $3.3 million the latest figure, recorded in Q3 2023.

• Quarterly Notes Payables fell 39.39% year-over-year to $3.3 million in Q3 2023, while the trailing twelve-month figure through Sep 2023 was $3.3 million (down 39.39% YoY) and the FY2022 annual result came in at $4.9 million, down 89.14% from the prior year.
• Notes Payables eased to $3.3 million in Q3 2023 per PRQR's latest filing, from $4.1 million in the prior quarter.
• Over the last five years, Notes Payables for PRQR reached as high as $44.7 million in Q4 2021 and fell as low as $108.11 in Q1 2019.
• A 5-year average of $13.6 million and a median of $5.6 million in 2020 frame the typical range for Notes Payables.
• Annual changes were most pronounced in 2019 — Notes Payables jumped 131019889.11% — and 2021, when it sank 99.87%.
• Year by year, Notes Payables stood at $390318.3 in 2019, then surged by 230.9% to $1.3 million in 2020, then jumped by 3364.23% to $44.7 million in 2021, then plunged by 89.14% to $4.9 million in 2022, then tumbled by 32.31% to $3.3 million in 2023.
• According to Business Quant data, Notes Payables over the past three periods registered $3.3 million, $4.1 million, and $4.4 million for Q3 2023, Q2 2023, and Q1 2023 respectively.